Abstract: Objective To evaluate the clinic efficacy of ezetimibe in treating patients with nonalcoholic fatty liver disease(NAFLD). Methods From April 2020 to october 2021,56 patients with NAFLD were selected and randomly divided into experimental group and control group. The experimental group was given ezetimibe in addition to the treatment received by the control group, in order to regualte cholesterol metabolism. The treatment course lasted 48 weeks. Clinical effficacy, serum biochemical indicators, and liver stiffness values were observed and compared before and after the treatment. Results After 48 weeks of treatment, the total curative effects in the experimental group and control groups were 92.85% and 67.85%, respectively. The difference was statistically significant (P< 0.05). The levels of ALT, AST, γ-GT, TC, TG, LDL-C in the experimental group were lower than those in the control group, with the differences being statistically significant (P<0.05). The liver stiffness value of the experimental group was lower than that of the control group after treatment, showing a significant difference between the two groups (6.21±0.99 kPa vs. 6.79±1.05 kPa, P<0.05). Conclusion Ezetimibe, by regulating cholesterol metabolism, can enhance liver function indices and reduce liver stiffness, thereby improving the clinical outcomes for patients with NAFLD.

Key words: Ezetimibe, Nonalcoholic fatty liver disease, Clinic effect